Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

This strategy can be considered a new standard of care and should be of great interest for health care payers and decision makers in an era in which our greatest challenge is to balance hard-won and incremental, yet small, improvements in patient outcomes with exponentially rising costs.